$ACHV
ACHIEVE LIFE SCIENCES, INC.

2024 Q1 Form 10-K Financial Statement

#000095017024038049 Filed on March 28, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.183M $2.272M $11.44M
YoY Change 4.57% 1.07% 6.66%
% of Gross Profit
Research & Development $2.799M $2.114M $15.81M
YoY Change -49.42% -75.46% -47.42%
% of Gross Profit
Depreciation & Amortization $57.00K $58.00K $228.0K
YoY Change -1.72% -10.77% -3.39%
% of Gross Profit
Operating Expenses $2.799M $4.386M $27.25M
YoY Change -49.42% -59.62% -9.4%
Operating Profit
YoY Change
Interest Expense $813.0K -$1.107M -$2.556M
YoY Change 41.88% 158.04% -242.87%
% of Operating Profit
Other Income/Expense, Net -$512.0K $17.00K -$9.000K
YoY Change 23.67% -71.19% -99.42%
Pretax Income -$6.494M -$5.476M -$29.82M
YoY Change -27.78% -51.25% -29.6%
Income Tax
% Of Pretax Income
Net Earnings -$6.500M -$5.476M -$29.82M
YoY Change -27.78% -51.25% -29.6%
Net Earnings / Revenue
Basic Earnings Per Share -$0.26 -$1.50
Diluted Earnings Per Share -$0.26 -$0.26 -$1.50
COMMON SHARES
Basic Shares Outstanding 34.25M 21.17M 19.83M
Diluted Shares Outstanding 25.05M 19.83M

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $66.40M $15.55M $15.55M
YoY Change 302.07% -37.24% -37.24%
Cash & Equivalents $66.40M $15.55M $15.55M
Short-Term Investments
Other Short-Term Assets $1.311M $1.325M $1.325M
YoY Change -19.12% -46.01% -46.01%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $67.71M $16.98M $16.98M
YoY Change 271.54% -37.86% -37.86%
LONG-TERM ASSETS
Property, Plant & Equipment $51.00K $66.00K $79.00K
YoY Change -25.0% 1550.0% -37.8%
Goodwill $1.034M $1.034M
YoY Change 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $94.00K $92.00K $79.00K
YoY Change -13.76% 39.39% 27.42%
Total Long-Term Assets $2.320M $2.389M $2.389M
YoY Change -9.87% -9.54% -9.54%
TOTAL ASSETS
Total Short-Term Assets $67.71M $16.98M $16.98M
Total Long-Term Assets $2.320M $2.389M $2.389M
Total Assets $70.03M $19.37M $19.37M
YoY Change 236.71% -35.37% -35.37%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $373.0K $618.0K $618.0K
YoY Change -64.91% -62.77% -62.77%
Accrued Expenses $2.479M $3.005M $3.005M
YoY Change -13.53% -22.31% -22.31%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $17.14M $16.66M $16.66M
YoY Change 4.7% 3.68% 3.68%
Total Short-Term Liabilities $20.57M $20.81M $20.81M
YoY Change 1.34% -3.64% -3.64%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $6.000K $6.000K
YoY Change -100.0% -91.3% -91.3%
Total Long-Term Liabilities $0.00 $6.000K $6.000K
YoY Change -100.0% -91.3% -91.3%
TOTAL LIABILITIES
Total Short-Term Liabilities $20.57M $20.81M $20.81M
Total Long-Term Liabilities $0.00 $6.000K $6.000K
Total Liabilities $20.57M $20.82M $20.82M
YoY Change 1.07% -3.92% -3.92%
SHAREHOLDERS EQUITY
Retained Earnings -$172.2M -$165.8M
YoY Change 18.84% 22.0%
Common Stock $221.7M $164.3M
YoY Change 52.51% 13.91%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $49.46M -$1.448M -$1.448M
YoY Change
Total Liabilities & Shareholders Equity $70.03M $19.37M $19.37M
YoY Change 236.71% -35.37% -35.37%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$6.500M -$5.476M -$29.82M
YoY Change -27.78% -51.25% -29.6%
Depreciation, Depletion And Amortization $57.00K $58.00K $228.0K
YoY Change -1.72% -10.77% -3.39%
Cash From Operating Activities -$5.300M -$4.359M -$24.48M
YoY Change -36.14% -60.88% -34.72%
INVESTING ACTIVITIES
Capital Expenditures $1.000K $21.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$1.000K -$21.00K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $15.53M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 56.11M -2.000K 15.28M
YoY Change 119282.98% -100.01% -20.82%
NET CHANGE
Cash From Operating Activities -5.300M -4.359M -24.48M
Cash From Investing Activities -1.000K -21.00K
Cash From Financing Activities 56.11M -2.000K 15.28M
Net Change In Cash 50.82M -4.362M -9.222M
YoY Change -715.5% -166.39% -49.47%
FREE CASH FLOW
Cash From Operating Activities -$5.300M -$4.359M -$24.48M
Capital Expenditures $1.000K $21.00K
Free Cash Flow -$4.360M -$24.50M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0000949858
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
BC
CY2022Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
033-80623
CY2023 dei Entity Registrant Name
EntityRegistrantName
Achieve Life Sciences, Inc.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
95-4343413
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
1040 West Georgia Street
CY2023 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 1030
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Vancouver
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
V6E 4H1
CY2023 dei City Area Code
CityAreaCode
604
CY2023 dei Local Phone Number
LocalPhoneNumber
210-2217
CY2023 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2023 dei Trading Symbol
TradingSymbol
ACHV
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
90759907
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
34251911
CY2023 dei Auditor Name
AuditorName
PricewaterhouseCoopers LLP
CY2023 dei Auditor Location
AuditorLocation
Vancouver, Canada
CY2023 dei Auditor Firm
AuditorFirmId
271
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15546000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24771000
CY2023Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
111000
CY2022Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
105000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1325000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2454000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
16982000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
27330000
CY2023Q4 achv Restricted Cash And Other Assets
RestrictedCashAndOtherAssets
92000
CY2022Q4 achv Restricted Cash And Other Assets
RestrictedCashAndOtherAssets
66000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
66000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
123000
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1197000
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1418000
CY2023Q4 us-gaap Goodwill
Goodwill
1034000
CY2022Q4 us-gaap Goodwill
Goodwill
1034000
CY2023Q4 us-gaap Assets
Assets
19371000
CY2022Q4 us-gaap Assets
Assets
29971000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
618000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1660000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
351000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
403000
CY2023Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
528000
CY2023Q4 achv Accrued Liabilities Clinical Current
AccruedLiabilitiesClinicalCurrent
280000
CY2022Q4 achv Accrued Liabilities Clinical Current
AccruedLiabilitiesClinicalCurrent
1729000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2311000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1678000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
63000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
58000
CY2023Q4 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
16662000
CY2022Q4 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
16071000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
20813000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
21599000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-33152000
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.5
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.5
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
69000
CY2023Q4 us-gaap Liabilities
Liabilities
20819000
CY2022Q4 us-gaap Liabilities
Liabilities
21668000
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21165760
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21165760
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17897029
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17897029
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
90000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
87000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
164209000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
144148000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-165751000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-135936000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
4000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
4000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-1448000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
8303000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
19371000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
29971000
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15814000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30078000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23966000
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11436000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10722000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9128000
CY2023 us-gaap Costs And Expenses
CostsAndExpenses
27250000
CY2022 us-gaap Costs And Expenses
CostsAndExpenses
40800000
CY2021 us-gaap Costs And Expenses
CostsAndExpenses
33094000
CY2023 us-gaap Investment Income Interest
InvestmentIncomeInterest
825000
CY2022 us-gaap Investment Income Interest
InvestmentIncomeInterest
199000
CY2021 us-gaap Investment Income Interest
InvestmentIncomeInterest
17000
CY2023 us-gaap Interest Expense
InterestExpense
2853000
CY2022 us-gaap Interest Expense
InterestExpense
1789000
CY2023 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
528000
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-9000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
40000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-75000
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2565000
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1550000
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-58000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-29815000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-42350000
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.08
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.08
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19827354
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19827354
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10593034
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10593034
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8119836
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8119836
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
37286000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2187000
CY2021 achv Shares Issued On Exercise Of Warrants Value
SharesIssuedOnExerciseOfWarrantsValue
338000
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
41000
CY2021 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-1000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-33152000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
28042000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3270000
CY2022 achv Shares Issued On Exercise Of Warrants Value
SharesIssuedOnExerciseOfWarrantsValue
24000
CY2022 achv Adjustments To Additional Paid In Capital Shares Issued Through At The Market Offering
AdjustmentsToAdditionalPaidInCapitalSharesIssuedThroughAtTheMarketOffering
1330000
CY2022 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
26000
CY2022 achv Stock Issued During Period Value Restricted Stock Unit Settlement Withheld And Retired To Treasury
StockIssuedDuringPeriodValueRestrictedStockUnitSettlementWithheldAndRetiredToTreasury
-47000
CY2022 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
126000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-42350000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
8303000
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3439000
CY2023 achv Shares Issued On Exercise Of Warrants Value
SharesIssuedOnExerciseOfWarrantsValue
227000
CY2023 achv Adjustment To Additional Paid In Capital Convertible Debt Refinancing Discount
AdjustmentToAdditionalPaidInCapitalConvertibleDebtRefinancingDiscount
1074000
CY2023 achv Stock Issued During Period Value Restricted Stock Unit Settlement Withheld And Retired To Treasury
StockIssuedDuringPeriodValueRestrictedStockUnitSettlementWithheldAndRetiredToTreasury
-220000
CY2023 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
273000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-29815000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-1448000
CY2023 us-gaap Profit Loss
ProfitLoss
-29815000
CY2022 us-gaap Profit Loss
ProfitLoss
-42350000
CY2021 us-gaap Profit Loss
ProfitLoss
-33152000
CY2023 us-gaap Depreciation And Amortization
DepreciationAndAmortization
228000
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
236000
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
250000
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
3439000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
3270000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
2187000
CY2023 achv Shares Issued As Settlement With Trade Vendor As Non Monetary Transaction
SharesIssuedAsSettlementWithTradeVendorAsNonMonetaryTransaction
273000
CY2022 achv Shares Issued As Settlement With Trade Vendor As Non Monetary Transaction
SharesIssuedAsSettlementWithTradeVendorAsNonMonetaryTransaction
26000
CY2021 achv Shares Issued As Settlement With Trade Vendor As Non Monetary Transaction
SharesIssuedAsSettlementWithTradeVendorAsNonMonetaryTransaction
41000
CY2023 achv Accrued Interest On Svb Convertible Debt
AccruedInterestOnSVBConvertibleDebt
-1216000
CY2022 achv Accrued Interest On Svb Convertible Debt
AccruedInterestOnSVBConvertibleDebt
-1170000
CY2023 achv Accretion Of Discount On Modification Of Debt
AccretionOfDiscountOnModificationOfDebt
430000
CY2023 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
528000
CY2023 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-1042000
CY2022 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
799000
CY2021 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
509000
CY2023 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-32000
CY2023 achv Increase Decrease In Grants Receivable
IncreaseDecreaseInGrantsReceivable
6000
CY2022 achv Increase Decrease In Grants Receivable
IncreaseDecreaseInGrantsReceivable
-48000
CY2021 achv Increase Decrease In Grants Receivable
IncreaseDecreaseInGrantsReceivable
153000
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1176000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
931000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
228000
CY2022 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
55000
CY2021 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-245000
CY2023 achv Increase Decrease In Accrued Clinical Liabilities
IncreaseDecreaseInAccruedClinicalLiabilities
-1449000
CY2022 achv Increase Decrease In Accrued Clinical Liabilities
IncreaseDecreaseInAccruedClinicalLiabilities
376000
CY2021 achv Increase Decrease In Accrued Clinical Liabilities
IncreaseDecreaseInAccruedClinicalLiabilities
899000
CY2023 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
633000
CY2022 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-263000
CY2021 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
466000
CY2023 achv Increase Decrease In Lease Obligations
IncreaseDecreaseInLeaseObligations
58000
CY2022 achv Increase Decrease In Lease Obligations
IncreaseDecreaseInLeaseObligations
5000
CY2021 achv Increase Decrease In Lease Obligations
IncreaseDecreaseInLeaseObligations
14000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-24479000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-37569000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29440000
CY2023 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
227000
CY2022 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
24000
CY2021 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
338000
CY2021 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
14929000
CY2022 achv Proceeds From At Market Offering
ProceedsFromAtMarketOffering
1330000
CY2022 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
126000
CY2023 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
220000
CY2022 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
47000
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
15278000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
19315000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
36610000
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
21000
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-21000
CY2023 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-3000
CY2022 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3000
CY2021 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-1000
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-9225000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-18251000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
7169000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
24821000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
43072000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
35903000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
15596000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
24821000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
43072000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-165800000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15500000
CY2023Q4 achv Working Capital Balance
WorkingCapitalBalance
3800000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-29800000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-24500000
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements in conformity with United States generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and notes thereto. Actual results could differ from these estimates. Estimates and assumptions principally relate to estimates of contingent considerations, the initial fair value and forfeiture rates of stock options issued to employees and consultants, the estimated compensation cost on performance restricted stock unit awards, clinical trial and manufacturing accruals, estimated useful lives of property, plant, equipment and intangible assets, estimates and assumptions in contingent liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2023 achv Maturity Period Of Highly Liquid Investments To Be Considered As Cash Equivalent
MaturityPeriodOfHighlyLiquidInvestmentsToBeConsideredAsCashEquivalent
P3M
CY2023 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023Q4 us-gaap Cash
Cash
400000
CY2023 achv Average Period To Maturity For Portfolio Of Cash And Marketable Securities
AveragePeriodToMaturityForPortfolioOfCashAndMarketableSecurities
P0D
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
22756000
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
22756000
CY2015Q2 us-gaap Finite Lived Intangible Assets Fair Value Disclosure
FiniteLivedIntangibleAssetsFairValueDisclosure
3100000
CY2015Q2 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P14Y
CY2023 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
200000
CY2022 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
200000
CY2023Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
223000
CY2023Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
223000
CY2023Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
223000
CY2023Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
223000
CY2023Q4 achv Finite Lived Intangible Assets Amortization Expense After Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour
305000
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1197000
CY2023 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
CY2023Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
14252000
CY2023Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
14252000
CY2023Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
50000
CY2023Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
50000
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
50000
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
50000
CY2023 achv Maximum Maturity Period Of Cash And Cash Equivalents
MaximumMaturityPeriodOfCashAndCashEquivalents
P90D
CY2023Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
15000000
CY2023Q4 us-gaap Convertible Debt
ConvertibleDebt
16662000
CY2023Q4 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
16652000
CY2022Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
15000000
CY2022Q4 us-gaap Convertible Debt
ConvertibleDebt
16071000
CY2022Q4 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
16987000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
256000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
243000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13000
CY2023Q2 us-gaap Debt Instrument Basis Spread On Variable Rate1
DebtInstrumentBasisSpreadOnVariableRate1
0.0225
CY2023Q2 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.07
CY2023Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
15000000
CY2022Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
15000000
CY2023Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
5000
CY2022Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
67
CY2023Q4 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
2311000
CY2022Q4 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
1138000
CY2023Q4 achv Discount On Modification Of Debt
DiscountOnModificationOfDebt
1074000
CY2023Q4 achv Accretion Of Discount On Modification Debt
AccretionOfDiscountOnModificationDebt
430000
CY2023Q4 us-gaap Convertible Debt
ConvertibleDebt
16662000
CY2022Q4 us-gaap Convertible Debt
ConvertibleDebt
16071000
CY2022 achv Future Income Tax Rate Assumed For Deferred Tax Calculations
FutureIncomeTaxRateAssumedForDeferredTaxCalculations
0.21
CY2021 achv Future Income Tax Rate Assumed For Deferred Tax Calculations
FutureIncomeTaxRateAssumedForDeferredTaxCalculations
0.21
CY2023 achv Future Income Tax Rate Assumed For Deferred Tax Calculations
FutureIncomeTaxRateAssumedForDeferredTaxCalculations
0.21
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-28982000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-41660000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-31411000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-833000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-690000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-1741000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-29815000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-42350000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-33152000
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-6261000
CY2022 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-8894000
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-6962000
CY2023 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
477000
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
299000
CY2021 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
224000
CY2023 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
-169000
CY2022 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
-18000
CY2021 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
17000
CY2023 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
-36000
CY2022 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
-26000
CY2021 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
-77000
CY2023 achv Income Tax Reconciliation Tax Credits Research And Development
IncomeTaxReconciliationTaxCreditsResearchAndDevelopment
883000
CY2022 achv Income Tax Reconciliation Tax Credits Research And Development
IncomeTaxReconciliationTaxCreditsResearchAndDevelopment
1154000
CY2021 achv Income Tax Reconciliation Tax Credits Research And Development
IncomeTaxReconciliationTaxCreditsResearchAndDevelopment
134000
CY2023 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
7686000
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
10464000
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
7544000
CY2022 achv Income Tax Reconciliation Reassessment Of Previously Recognized Net Operating Losses
IncomeTaxReconciliationReassessmentOfPreviouslyRecognizedNetOperatingLosses
9000
CY2021 achv Income Tax Reconciliation Reassessment Of Previously Recognized Net Operating Losses
IncomeTaxReconciliationReassessmentOfPreviouslyRecognizedNetOperatingLosses
-620000
CY2023 achv Income Tax Reconciliation Adjustment To Prior Year Research And Development Tax Credits
IncomeTaxReconciliationAdjustmentToPriorYearResearchAndDevelopmentTaxCredits
760000
CY2022 achv Income Tax Reconciliation Adjustment To Prior Year Research And Development Tax Credits
IncomeTaxReconciliationAdjustmentToPriorYearResearchAndDevelopmentTaxCredits
731000
CY2023 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-54000
CY2022 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
51000
CY2021 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
8000
CY2023Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
899000
CY2022Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
899000
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
48867000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
43380000
CY2023Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
10716000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
8942000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1134000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1042000
CY2023Q4 achv Deferred Tax Assets Capitalized Research And Development Expenses
DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses
11528000
CY2022Q4 achv Deferred Tax Assets Capitalized Research And Development Expenses
DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses
11342000
CY2023Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
434000
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
334000
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
73578000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
65939000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
73232000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
65546000
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
346000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
393000
CY2023Q4 achv Deffered Tax Liabilities Right Of Use Assets
DefferedTaxLiabilitiesRightOfUseAssets
91000
CY2022Q4 achv Deffered Tax Liabilities Right Of Use Assets
DefferedTaxLiabilitiesRightOfUseAssets
91000
CY2023Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
255000
CY2022Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
302000
CY2023Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
346000
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
393000
CY2023Q4 achv Deferred Tax Assets Liabilities Valuation Allowance
DeferredTaxAssetsLiabilitiesValuationAllowance
73200000
CY2023Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
7700000
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2022Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
761000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
761000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
767000
CY2023 achv Unrecognized Tax Benefits Increases Decrease Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesDecreaseResultingFromPriorPeriodTaxPositions
0
CY2022 achv Unrecognized Tax Benefits Increases Decrease Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesDecreaseResultingFromPriorPeriodTaxPositions
0
CY2021 achv Unrecognized Tax Benefits Increases Decrease Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesDecreaseResultingFromPriorPeriodTaxPositions
6000
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
761000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
761000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
761000
CY2023Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
800000
CY2022Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2023Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2023 us-gaap Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
139750
CY2022 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2022 us-gaap Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
26625
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.036
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0165
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y9M
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y9M18D
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.1519
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.228
CY2023 achv Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeiture Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate
0
CY2022 achv Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeiture Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate
0
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.4
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
3439000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
3270000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
822515
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
18.57
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
639500
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.23
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
35
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
25555.2
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1461980
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.12
CY2023Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
1461980
CY2023Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
12.12
CY2023 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P8Y21D
CY2023Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
661118
CY2023Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
19.25
CY2023 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
P7Y2M4D
CY2023Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
3400000
CY2022Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
3200000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-29815000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-42350000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-33152000
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19827354
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19827354
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10593034
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10593034
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8119836
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8119836
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.5
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.5
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.08
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.08
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7058883000000
CY2023Q4 us-gaap Contractual Obligation
ContractualObligation
74000
CY2023Q4 us-gaap Contractual Obligation Due In Next Twelve Months
ContractualObligationDueInNextTwelveMonths
68000
CY2023Q4 us-gaap Contractual Obligation Due In Second And Third Year
ContractualObligationDueInSecondAndThirdYear
6000
CY2023 us-gaap Operating Lease Expense
OperatingLeaseExpense
100000
CY2022 us-gaap Operating Lease Expense
OperatingLeaseExpense
100000
CY2021 us-gaap Operating Lease Expense
OperatingLeaseExpense
100000
CY2023 us-gaap Operating Lease Payments
OperatingLeasePayments
57000
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
59000
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
120000
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y29D
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y29D
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0898
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0898
CY2023Q4 us-gaap Guarantee Obligations Current Carrying Value
GuaranteeObligationsCurrentCarryingValue
0
CY2023 achv Indemnification Expense
IndemnificationExpense
0

Files In Submission

Name View Source Status
0000950170-24-038049-index-headers.html Edgar Link pending
0000950170-24-038049-index.html Edgar Link pending
0000950170-24-038049.txt Edgar Link pending
0000950170-24-038049-xbrl.zip Edgar Link pending
achv-20231231.htm Edgar Link pending
achv-20231231.xsd Edgar Link pending
achv-ex10_10.htm Edgar Link pending
achv-ex10_21.htm Edgar Link pending
achv-ex10_32.htm Edgar Link pending
achv-ex21_1.htm Edgar Link pending
achv-ex23_1.htm Edgar Link pending
achv-ex31_1.htm Edgar Link pending
achv-ex32_1.htm Edgar Link pending
achv-ex97_0.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
achv-20231231_htm.xml Edgar Link completed